secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2025-10-09T23:59:59+00:00
Accession:  0001404644-25-000088
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene FDA agreement on Rett gene therapy registrational trial; Q4 2025 dosing start
--------------------------------------------------------------------------------

- Completed FDA discussions on Embolden registrational trial protocol for NGN-401; first participant dosing planned in Q4 2025 across 13 U.S. sites.
- New preclinical NHP data shows ICV delivery achieves superior brain biodistribution vs. IT-L at clinically relevant 1E15 vg dose; supports ICV route.
- Phase 1/2 data: first 4 participants gained 23 developmental milestones across multiple domains, indicating multi-domain improvement.
- ICV and IT-L show comparable peripheral organ transduction; no liver-sparing benefit to IT-L administration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000088/0001404644-25-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000088/ngne-20251009.htm
  HTML page:      https://secwatch.observer/filing/0001404644-25-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer